Last reviewed · How we verify
verteporfin, bevacizumab, triamcinolone acetonide
verteporfin, bevacizumab, triamcinolone acetonide is a photosensitizer, monoclonal antibody, corticosteroid Small molecule drug developed by Shahid Beheshti University of Medical Sciences. It is currently in Phase 3 development for Treatment of choroidal neovascularization in age-related macular degeneration, Treatment of macular edema following retinal vein occlusion, Treatment of metastatic colorectal cancer.
Verteporfin is a photosensitizer that selectively targets and destroys abnormal blood vessels in the eye, while bevacizumab is a monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor A (VEGF-A), and triamcinolone acetonide is a corticosteroid that reduces inflammation and swelling.
Verteporfin is a photosensitizer that selectively targets and destroys abnormal blood vessels in the eye, while bevacizumab is a monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor A (VEGF-A), and triamcinolone acetonide is a corticosteroid that reduces inflammation and swelling. Used for Treatment of choroidal neovascularization in age-related macular degeneration, Treatment of macular edema following retinal vein occlusion, Treatment of metastatic colorectal cancer.
At a glance
| Generic name | verteporfin, bevacizumab, triamcinolone acetonide |
|---|---|
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Drug class | photosensitizer, monoclonal antibody, corticosteroid |
| Target | VEGF-A, VEGF receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology, Oncology |
| Phase | Phase 3 |
Mechanism of action
Verteporfin works by accumulating in abnormal blood vessels and releasing energy when exposed to light, causing damage to the vessel walls. Bevacizumab binds to VEGF-A, preventing it from interacting with its receptor and thereby inhibiting the formation of new blood vessels. Triamcinolone acetonide reduces inflammation and swelling by suppressing the production of inflammatory mediators.
Approved indications
- Treatment of choroidal neovascularization in age-related macular degeneration
- Treatment of macular edema following retinal vein occlusion
- Treatment of metastatic colorectal cancer
Common side effects
- Visual disturbances
- Increased intraocular pressure
- Hypersensitivity reactions
- Nausea
- Vomiting
Key clinical trials
- Combination Therapy for Age-Related Macular Degeneration. (PHASE2)
- TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration (PHASE2)
- Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- verteporfin, bevacizumab, triamcinolone acetonide CI brief — competitive landscape report
- verteporfin, bevacizumab, triamcinolone acetonide updates RSS · CI watch RSS
- Shahid Beheshti University of Medical Sciences portfolio CI
Frequently asked questions about verteporfin, bevacizumab, triamcinolone acetonide
What is verteporfin, bevacizumab, triamcinolone acetonide?
How does verteporfin, bevacizumab, triamcinolone acetonide work?
What is verteporfin, bevacizumab, triamcinolone acetonide used for?
Who makes verteporfin, bevacizumab, triamcinolone acetonide?
What drug class is verteporfin, bevacizumab, triamcinolone acetonide in?
What development phase is verteporfin, bevacizumab, triamcinolone acetonide in?
What are the side effects of verteporfin, bevacizumab, triamcinolone acetonide?
What does verteporfin, bevacizumab, triamcinolone acetonide target?
Related
- Drug class: All photosensitizer, monoclonal antibody, corticosteroid drugs
- Target: All drugs targeting VEGF-A, VEGF receptor
- Manufacturer: Shahid Beheshti University of Medical Sciences — full pipeline
- Therapeutic area: All drugs in Ophthalmology, Oncology
- Indication: Drugs for Treatment of choroidal neovascularization in age-related macular degeneration
- Indication: Drugs for Treatment of macular edema following retinal vein occlusion
- Indication: Drugs for Treatment of metastatic colorectal cancer
- Compare: verteporfin, bevacizumab, triamcinolone acetonide vs similar drugs
- Pricing: verteporfin, bevacizumab, triamcinolone acetonide cost, discount & access